

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI922752

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	Christopher Zoumalan	03/30/2025
RECEIVING PARTY DATA		
Company Name:	MD Medical Designs, Inc.	
Street Address:	433 N Camden Dr.	
Internal Address:	Ste. 1090	
City:	Beverly Hills	
State/Country:	CALIFORNIA	
Postal Code:	90210	
PROPERTY NUMBERS Total: 6		
Property Type	Number	
Application Number:	62442423	
Patent Number:	10496949	
PCT Number:	US1812264	
Application Number:	16574974	
Patent Number:	11213473	
Application Number:	17539101	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	213)816-5366	
Email:	billf@fitzpatrickip.com	
Correspondent Name:	William Fitzpatrick	
Address Line 1:	626 Wilshire Blvd	
Address Line 2:	Ste 410	
Address Line 4:	Los Angeles , CALIFORNIA 90017	
ATTORNEY DOCKET NUMBER:	Zou_200	
NAME OF SUBMITTER:	William Fitzpatrick	
SIGNATURE:	/William Fitzpatrick/	
DATE SIGNED:	03/31/2025	

PATENT

Total Attachments: 3

source=Zou_200_Patent_Assignment_March_29_2025#page1.tiff

source=Zou_200_Patent_Assignment_March_29_2025#page2.tiff

source=Zou_200_Patent_Assignment_March_29_2025#page3.tiff

PATENT

REEL: 070677 FRAME: 0740

ASSIGNMENT

In accordance with my obligations arising under certain agreements, or where applicable, for other good and valuable consideration, the receipt of which is hereby acknowledged, I,

Christopher Zoumalan of Los Angeles, CA, USA

hereby assign, transfer and convey all of my right, title and interest in and to the patents and/or patent applications listed in Exhibit A to:

MD Medical Designs, Inc.


433 N Camden Dr.

Suite 1090

Beverly Hills, California 90210

hereinafter referred to as “Company”, its successors and assigns, and any further non-provisional application, and/or divisions, continuations, reexaminations and reissues resulting therefrom, all foreign filings, and all rights of priority resulting from the filing of said United States application, and authorize and request any official whose duty it is to issue patents, to issue the non-provisional application and/or divisions and/or continuations, reexaminations and reissues on said invention resulting therefrom to said Company, or its successors or assigns and agree that on request and without further consideration, but at the expense of said Company, I will communicate to said Company or its representatives or nominees any facts known to us respecting said invention and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuations, reexamination and reissue applications, make all rightful oaths and generally do everything possible to aid said Company, its successors and assigns, to obtain and enforce proper patent protection for said invention in all countries.


Name: Christopher Zoumalan

Signature:  _____

Date: 3/30/25

Witness Name: Rhonda Kalasho


Date: 3/30/25

Witness Signature:  _____

MD Medical Designs, Inc.

Name: Christopher Zoumalan .

Position: CEO

Signature:  _____

Date: 3/30/25

. .

Exhibit A

Docket No.	Country	Patent No. or Application No.	Type	Priority Date	Title	Status	Next Step	Expiration Date
201_1pr	US	62/442423	Provisional Utility	2017-01-04	COMPOSITIONS AND METHODS FOR TREATING CUTANEOUS CONDITIONS	Converted	NA	NA
201_2us	US	10,496,949	Non-Provisional Utility	2017-01-04	COMPOSITIONS AND METHODS FOR TREATING CUTANEOUS CONDITIONS	Issued Patent	7.5 year Maintenance Fee Window Opens on December 3, 2026	2037-11-07
201_3wo	WIPO	PCT/US18/12264	Non-Provisional Utility	2017-01-04	COMPOSITIONS AND METHODS FOR TREATING CUTANEOUS CONDITIONS	NA	NA	NA
201_4con	US	16/574974	Non-Provisional Utility	2017-01-04	COMPOSITIONS AND METHODS FOR TREATING CUTANEOUS CONDITIONS	ABN – Cost Out Savings	NA	NA
202_1us	US	11,213,473	Non-Provisional Utility	2020-09-18	SKIN BRIGHTENING COMPOSITION	Issued Patent	3.5 Year Maintenance Fee Due July 8, 2025	2040-09-18
202_2con	US	17/539101	Non-Provisional Utility	2020-09-18	SKIN BRIGHTENING COMPOSITION	ABN – Cost Out Savings	NA	NA